Safety, Efficacy and Pharmacokinetics of AZD7442 (tixagevimab/cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial.
INFECTIOUS DISEASES AND THERAPY（2024）
Key words
Tixagevimab,Cilgavimab,COVID-19,Monoclonal antibody,Clinical trial
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined